MENU
+Compare
LFSC
ETF ticker: NASDAQ
AS OF
Jan 14, 04:17 PM (EDT)
Price
$36.16
Change
+$0.46 (+1.29%)

LFSC stock forecast, quote, news & analysis

The investment seeks long-term capital appreciation... Show more

Category: #Health
LFSC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for LFSC with price predictions
Jan 13, 2026

LFSC's Indicator enters downward trend

The Aroon Indicator for LFSC entered a downward trend on January 08, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 29 similar instances where the Aroon Indicator formed such a pattern. In of the 29 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for LFSC moved out of overbought territory on December 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 14 cases where LFSC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on December 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LFSC as a result. In of 14 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LFSC turned negative on December 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at .

LFSC moved below its 50-day moving average on January 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFSC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LFSC advanced for three days, in of 65 cases, the price rose further within the following month. The odds of a continued upward trend are .

LFSC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Guardant Health (NASDAQ:GH), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks long-term capital appreciation. The fund is an actively managed exchange-traded fund (“ETF”) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund’s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.

Market Cap

The average market capitalization across the F/m Emerald Life Sciences Innovation ETF ETF is 6.03B. The market cap for tickers in the group ranges from 586.47M to 34.92B. INSM holds the highest valuation in this group at 34.92B. The lowest valued company is OFIX at 586.47M.

High and low price notable news

The average weekly price growth across all stocks in the F/m Emerald Life Sciences Innovation ETF ETF was 7%. For the same ETF, the average monthly price growth was 16%, and the average quarterly price growth was 166%. BHVN experienced the highest price growth at 14%, while ATEC experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the F/m Emerald Life Sciences Innovation ETF ETF was 17%. For the same stocks of the ETF, the average monthly volume growth was 79% and the average quarterly volume growth was 37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 71
P/E Growth Rating: 76
Price Growth Rating: 48
SMR Rating: 85
Profit Risk Rating: 74
Seasonality Score: 10 (-100 ... +100)
View a ticker or compare two or three
LFSC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details